X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare AJANTA PHARMA with WYETH LTD - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs WYETH LTD - Comparison Results

WYETH LTD 
   Change

Wyeth Limited is the 51% subsidiary of Wyeth, US and is the sixth largest company among multinationals with revenues of Rs 2.9 bn in FY07. The company derives its revenues from pharmaceutical and OTC segments with focus on various therapeutic areas s... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA WYETH LTD AJANTA PHARMA/
WYETH LTD
 
P/E (TTM) x 24.2 27.7 87.4% View Chart
P/BV x 10.0 5.3 186.7% View Chart
Dividend Yield % 0.6 1.3 47.2%  

Financials

 AJANTA PHARMA   WYETH LTD
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-16
WYETH LTD
Mar-13
AJANTA PHARMA/
WYETH LTD
5-Yr Chart
Click to enlarge
High Rs1,7201,044 164.7%   
Low Rs1,103818 134.8%   
Sales per share (Unadj.) Rs194.6298.6 65.2%  
Earnings per share (Unadj.) Rs45.257.2 79.0%  
Cash flow per share (Unadj.) Rs50.358.4 86.1%  
Dividends per share (Unadj.) Rs8.0017.00 47.1%  
Dividend yield (eoy) %0.61.8 31.0%  
Book value per share (Unadj.) Rs132.0249.5 52.9%  
Shares outstanding (eoy) m88.7722.72 390.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x7.33.1 232.6%   
Avg P/E ratio x31.216.3 191.9%  
P/CF ratio (eoy) x28.115.9 176.0%  
Price / Book Value ratio x10.73.7 286.4%  
Dividend payout %17.729.7 59.6%   
Avg Mkt Cap Rs m125,29921,157 592.2%   
No. of employees `000NA0.5 0.0%   
Total wages/salary Rs m2,570400 642.5%   
Avg. sales/employee Rs ThNM13,787.4-  
Avg. wages/employee Rs ThNM813.0-  
Avg. net profit/employee Rs ThNM2,643.3-  
INCOME DATA
Net Sales Rs m17,2756,783 254.7%  
Other income Rs m166353 47.2%   
Total revenues Rs m17,4427,136 244.4%   
Gross profit Rs m5,8071,617 359.1%  
Depreciation Rs m45127 1,694.0%   
Interest Rs m496 889.1%   
Profit before tax Rs m5,4741,938 282.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-5 0.0%   
Tax Rs m1,460632 230.9%   
Profit after tax Rs m4,0141,301 308.7%  
Gross profit margin %33.623.8 141.0%  
Effective tax rate %26.732.6 81.7%   
Net profit margin %23.219.2 121.2%  
BALANCE SHEET DATA
Current assets Rs m7,6396,984 109.4%   
Current liabilities Rs m2,7152,056 132.0%   
Net working cap to sales %28.572.6 39.2%  
Current ratio x2.83.4 82.8%  
Inventory Days Days4399 43.5%  
Debtors Days Days7924 328.6%  
Net fixed assets Rs m6,914244 2,830.0%   
Share capital Rs m177227 77.9%   
"Free" reserves Rs m11,4425,441 210.3%   
Net worth Rs m11,7215,668 206.8%   
Long term debt Rs m14925 594.8%   
Total assets Rs m14,8147,901 187.5%  
Interest coverage x112.9353.3 32.0%   
Debt to equity ratio x00 287.6%  
Sales to assets ratio x1.20.9 135.8%   
Return on assets %27.416.5 165.9%  
Return on equity %34.222.9 149.3%  
Return on capital %46.534.0 136.7%  
Exports to sales %55.10.2 25,276.7%   
Imports to sales %6.036.3 16.5%   
Exports (fob) Rs m9,52715 64,372.3%   
Imports (cif) Rs m1,0382,465 42.1%   
Fx inflow Rs m10,42215 68,564.5%   
Fx outflow Rs m1,6782,677 62.7%   
Net fx Rs m8,744-2,662 -328.5%   
CASH FLOW
From Operations Rs m3,264923 353.5%  
From Investments Rs m-2,093317 -660.4%  
From Financial Activity Rs m-1,186-481 246.5%  
Net Cashflow Rs m-15759 -1.9%  

Share Holding

Indian Promoters % 73.8 0.0 -  
Foreign collaborators % 0.0 51.1 -  
Indian inst/Mut Fund % 1.6 11.3 13.7%  
FIIs % 7.6 7.2 105.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.0 30.4 55.9%  
Shareholders   20,968 21,978 95.4%  
Pledged promoter(s) holding % 4.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   STERLING BIOTECH  SANOFI INDIA  ALEMBIC PHARMA  ORCHID PHARMA LTD  NOVARTIS  

Compare AJANTA PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes Marginally Lower; Capital Goods & Realty Stocks Fall(Closing)

Indian share markets witnessed selling pressure in the final hour of trade to finish just below the dotted line. At the closing bell, the BSE Sensex closed lower by 71 points.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Follow India's Super Investors to Make Big Money in the Market Crash(The 5 Minute Wrapup)

Feb 8, 2018

Has the sell-off in the markets left India's super investors unduly worried?

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

Rising Dominance of Mutual Funds(Chart Of The Day)

Feb 8, 2018

Domestic money flow into Indian equities surpassed foreign fund flows in the recent years. But will it continue in volatile market?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Feb 20, 2018 (Close)

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA 8-QTR ANALYSIS

COMPARE AJANTA PHARMA WITH

MARKET STATS